0001209191-17-032211.txt : 20170512
0001209191-17-032211.hdr.sgml : 20170512
20170512195410
ACCESSION NUMBER: 0001209191-17-032211
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20170510
FILED AS OF DATE: 20170512
DATE AS OF CHANGE: 20170512
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BELLICUM PHARMACEUTICALS, INC
CENTRAL INDEX KEY: 0001358403
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 201450200
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2130 WEST HOLCOMBE BOULEVARD
STREET 2: SUITE 800
CITY: HOUSTON
STATE: TX
ZIP: 77030
BUSINESS PHONE: (832) 384-1100
MAIL ADDRESS:
STREET 1: 2130 WEST HOLCOMBE BOULEVARD
STREET 2: SUITE 800
CITY: HOUSTON
STATE: TX
ZIP: 77030
FORMER COMPANY:
FORMER CONFORMED NAME: BELLICUM PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20060405
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Smith Alan K.
CENTRAL INDEX KEY: 0001705246
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36783
FILM NUMBER: 17840659
MAIL ADDRESS:
STREET 1: C/O BELLICUM PHARMACEUTICALS, INC.
STREET 2: 2130 W. HOLCOMBE BLVD., STE. 800
CITY: HOUSTON
STATE: TX
ZIP: 77030
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2017-05-10
0
0001358403
BELLICUM PHARMACEUTICALS, INC
BLCM
0001705246
Smith Alan K.
C/O BELLICUM PHARMACEUTICALS, INC.
2130 W. HOLCOMBE BLVD., STE. 800
HOUSTON
TX
77030
0
1
0
0
EVP, Technical Oprations
Common Stock
874
D
Stock Option (right to buy)
13.99
2025-10-18
Common Stock
75000
D
Stock Option (right to buy)
19.00
2026-01-03
Common Stock
37500
D
Stock Option (right to buy)
13.89
2027-01-02
Common Stock
11250
D
Restricted Stock Units
Common Stock
6250
D
25% of the shares subject to the stock option vest and become exercisable on October 19, 2016, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
25% of the shares subject to the stock option vest and become exercisable on January 4, 2017, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
25% of the shares subject to the stock option vest and become exercisable on January 3, 2018, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
The restricted stock units vest in four equal annual installments beginning on January 3, 2018.
Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
/s/ Alan K. Smith, Ph.D.
2017-05-12
EX-24.3_723537
2
poa.txt
POA DOCUMENT
POWER OF ATTORNEY
Know all, by these presents, that the undersigned hereby constitutes and
appoints each of Richard A. Fair, Ken Moseley and Alan Musso, signing
individually, the undersigned's true and lawful attorneys-in-fact and agents to:
(1) execute for and on behalf of the undersigned, an officer, director or holder
of 10% of more of a registered class of securities of Bellicum Pharmaceuticals,
Inc. (the "Company"), Forms 3, 4 and 5 in accordance with Section 16(a) of the
Securities Exchange Act of 1934, as amended (the "Exchange Act") and the rules
thereunder;
(2) do and perform any and all acts for and on behalf of the undersigned that
may be necessary or desirable to complete and execute such Form 3, 4 or 5,
complete and execute any amendment or amendments thereto, and timely file such
forms or amendments with the United States Securities and Exchange Commission
and any stock exchange or similar authority; and
(3) take any other action of any nature whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in
the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, are not assuming,
nor is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Exchange Act.
This Power of Attorney shall remain in full force and effect until the earliest
to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5
with respect to the undersigned's holdings of and transactions in securities
issued by the Company, (b) revocation by the undersigned in a signed writing
delivered to the foregoing attorneys-in-fact or (c) as to any attorney-in-fact
individually, until such attorney-in-fact shall no longer be employed by the
Company.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 26th day of April, 2017.
/s/ Alan K. Smith
(Signature)
Alan K. Smith, Ph.D.
(Print Name)